Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 12 Jun 2018 11:54 AM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Epilepsy Research Program (ERP) to explore the causative links between traumatic brain injury (TBI) and epilepsy, with the hope that, one day, post-traumatic epilepsy (PTE) will be preventable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    FY18 ERP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

     

    Applications should also address at least one of the ERP FY18 Focus Areas.  An application that proposes research outside of the FY18 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

     

    The ERP FY18 Focus Areas are as follows:

     

    Epidemiology:  Epidemiological characterization of PTE following TBI, which may include:

    • Risk factors such as demographics, genetic factors, organic head injury factors, or type of insult
    • Differentiation of PTE and Psychogenic Non-Epileptic Seizures (PNES)
    • Outcomes including latency to epilepsy, morbidities and comorbidities, and mortality
    • Pre-existing conditions including psychological and psychiatric risk factors
    • Treatment

    Markers and Mechanisms:  Identifying markers or mechanisms (via clinical prospective or preclinical models) that address PTE, which may include the following:

    • ·         Early detection
    • Diagnosis
    • Prognosis
    • Morbidity
    • Comorbidity
    • Mortality
    • Risk stratification

     

    Note:  Research considering the development of new models or better characterization of existing etiologically relevant models for PTE, including repetitive TBI, could be considered under this Focus Area.

     

    Longitudinal Studies:  Studies of the natural evolution of PTE, which may include the following:

    • Seizure frequency and severity
    • Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
    • Latency between injury and PTE
    • Mortality
    • Treatment
    • Quality of life of individuals with PTE

     

    http://cdmrp.army.mil/funding/erp

     

    Longitudinal Risk Factors Award – Preproposal due July 26, 2018

    The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Investigators must have a patient cohort identified.

    Intent:  To facilitate high-impact, systematic, cohort-based research investigating the natural evolution of PTE from TBI.

    ·         Responsive to the Longitudinal Focus Area Only.

    ·         Preliminary data are required.

    ·         Must describe how the inter-relationship between TBI and PTE will be assessed or characterized.

    ·         Must describe the nature of the cohort (military, etc.)

    ·         Must describe the study outcomes to be captured.

    ·         Must describe the nature of the TBIs within the study cohort.

    ·         Requires a Biostatistician.

    ·         Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.

    • ·         Research considering a pharmacologic intervention is specifically discouraged under this mechanism.
    • Maximum funding of $2,500,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.
    • ·         Indirect costs may be proposed in accordance with the institution's rate agreement.

     

     

    Idea Development Award –Letter of Intent due September 20, 2018

    Level I:  The Principal Investigator must be at or above the level of postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent).  

    Level II:  The Principal Investigator must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To solicit research to understand the magnitude and underlying mechanisms of PTE, especially in Service members and Veterans, while also benefitting the civilian community. 

    ·       Level I is intended to support high-risk or high-gain research from researchers at or above the level of a post-doctoral fellow (or equivalent). 

    ·       Level II is intended to support a more mature, hypothesis-driven research project.

    The following Focus Areas are open to both Levels I and II:

    ·         Epidemiology

    ·         Markers and Mechanisms

    ·         Longitudinal Studies

    ·         Preliminary data, while not required, are encouraged for both levels.

    Research considering a pharmacologic intervention is specifically discouraged under this mechanism.

    Level I:

    ·       Maximum funding of $300,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 2 years.

    ·       Indirect costs may be proposed in accordance with the institution's rate agreement.

    Level II:

    ·       Maximum funding of $500,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 3 years.

    Indirect costs may be proposed in accordance with the institution's rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk

    301-682-5507

    help@eBrap.org


  • 12 Jun 2018 11:08 AM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $15 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support the United States Medical Research Acquisition Activity.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY18 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    http://cdmrp.army.mil/funding/kcrp

     

    Concept Award – Letter of Intent due July 11, 2018

    Investigators at all academic levels.

    ·       Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

    ·       Emphasis on innovation.

    ·       Funding for clinical trials is not allowed.

    ·       Preliminary data are not allowed.

    ·       Blinded review

    ·      Maximum funding of $75,000 for direct costs (plus indirect costs).

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·       Maximum period of performance is 1 year.

     

    Idea Development Award – Letter of Intent due September 5, 2018

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

    Early Career Investigators:

    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

    ·       Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

    ·       Preliminary data are required.

    ·       Innovation and Impact are the most important review criteria.

    ·       Clinical trials are not allowed.

    ·       FY18 KCRP Areas of Emphasis are strongly encouraged.

    ·       Maximum funding of $400,000 in direct costs (plus indirect costs).

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·       Period of performance is not to exceed 2 years.

     

    Physicians Research Award – Letter of Intent due September 5, 2018

    The PI must be a physician with clinical duties and/or responsibilities who, at the application submission deadline, is within 3 years of having initiated his/her first appointment as an Instructor, Assistant Professor, or equivalent

    ·       Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research.

    ·       This award emphasizes equally the quality of the proposed research project and the career development of the Principal Investigator (PI), which should prepare physicians for careers in basic, population science, translational, or clinical kidney cancer research.

    ·       Clinical trials are not allowed.

    ·       Preliminary data are not required.

    ·       Maximum funding of $200,000 in direct costs (plus indirect costs).

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·       Period of performance is not to exceed 2 years.

     

    Technology Development Award – Letter of Intent due September 5, 2018

    Investigators at or above the level of Assistant Professor (or equivalent) are eligible.

    Applicants with limited kidney cancer experience are strongly encouraged to collaborate with those having substantial expertise in kidney cancer research and/or kidney cancer model systems.

    ·       Supports emerging technologies to aid clinical and patient outcomes.

    ·       Product-driven award intended to advance the development of technologies to aid clinical and patient outcomes, including prevention, detection, diagnosis, treatment, or quality of life.

    ·       Transition plan is required.

    ·       Clinical trials are not allowed.

    ·       Preliminary data are required (need not be in kidney cancer).

    ·       Maximum funding of $300,000 in direct costs (plus indirect costs).

    ·       Period of performance is not to exceed 3 years.

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

     

    Translational Research Partnership – Letter of Intent due September 5, 2018

    The Initiating PI must be at or above the level of Assistant Professor (or equivalent).

    The Partnering PI must be at or above the level of Assistant Professor or equivalent.  Postdoctoral fellows are not eligible to be Partnering PI’s.

    ·       Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

    ·       Supports translational correlative studies.

    ·       Preliminary data are required.

    ·       Clinical trials are not allowed.

    ·       Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·       Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 31 May 2018 12:31 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The RTRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 RTRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

    Focus Areas:  The FY18 RTRP encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA) in the following focus areas:

    • ·        Reduce the risks of VCA-associated immunotherapy
    • ·        Revolutionize ex vivo VCA tissue preservation strategies to extend the timeline between procurement and transplantation
    • ·        Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

    http://cdmrp.army.mil/pubs/press/2018/18rtrppreann

    Concept Award (CA)

    Investigators at or above the level of postdoctoral fellow (or equivalent)

    • Pre-application (Letter of Intent) is required.
    • Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
    • Preliminary data are NOT allowed.
    • Reviewers at both tiers of review will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organizations.
    • Applications must address at least one of the FY18 RTRP Focus Areas.

    ·      Maximum funding of $200,000 for total costs (direct plus indirect costs)

    • ·      Maximum period of performance is 18 months

     

    Investigator-Initiated Research Award (IIRA)

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; full application submission is by invitation only.
    • Supports studies with potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
    • Preliminary or published data required.
    • Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
    • Applications must address at least one of the FY18 RTRP Focus Areas.

    Individual PIs:

    ·      Maximum funding of $1 million (M) for total costs

    ·      Maximum period of performance is 3 years

    Multiple PI Option:

    ·      Maximum funding of $1.5M for total costs

    • ·      Maximum period of performance is 3 years

     

    Qualitative Research Award (QRA)

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; full application submission is by invitation only.
    • Supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering, or have already received, reconstructive transplant surgery.
    • Demonstrated qualitative research experience within the research team is required.
    • Applications must address the following FY18 RTRP Focus Area:

           Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

    Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

    ·      Maximum funding of $1M for total costs

    ·      Maximum period of performance is 3 years

     

    Multiple PI Option:

    ·      Maximum funding of $1.5M for total costs

    • ·      Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 31 May 2018 12:31 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $10 million (M) to the Department of Defense Hearing Restoration Research Program (HRRP) to support innovative, high-impact hearing restoration research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY18 HRRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

    The mission of the HRRP is to advance the science of hearing restoration by delivering groundbreaking research and solutions that remove barriers to the successful treatment of auditory system injury. Applications submitted to the FY18 HRRP must addresses one or more of the following Focus Areas (revised for FY18):

    • Develop reliable in vitro human models for evaluating hearing restoration therapies.
    • Accelerate translation of biological regeneration mechanisms into therapies that restore auditory function.
    • Develop and or validate techniques/methods to assess and or treat auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders.

    http://cdmrp.army.mil/funding/hrrp

    Translational Research Award (TRA) – Preproposal due July 17, 2018

    • Independent investigators at all academic levels (or equivalent)
    • Preproposal is required; application submission is by invitation only.
    • Supports animal and human studies to:
    • develop reliable in vitro human models for evaluating hearing restoration therapies, or
    • Accelerate translation of biological regeneration into therapies that restore auditory function, including, for example, synaptic plasticity and hair cell and neural regeneration.
    • Preliminary data required.
    • Clinical trials are not allowed.
    • Maximum funding of $1M for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Focused Research Award (FRA) – Preproposal due July 17, 2018

    • Independent investigators at all academic levels (or equivalent)
    • Preproposal is required; application submission is by invitation only.
    • Supports animal and human studies to develop and/or validate techniques and/or methods to assess and/or treat auditory dysfunction as related to synaptopathy, hidden hearing loss, and central auditory processing disorders. Examples include:
      • field tool(s) to diagnose hidden hearing loss and to inform operational readiness;
      • batteries of differential diagnostics tests that pinpoint the location(s) of auditory damage;
      • treatments for the various types of damage that result in the loss of hearing leading to decreased operational readiness.
    • Preliminary data required.
    • Clinical trials are not allowed.
    • Maximum funding of $1M for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Extramural applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the HRRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk 
    301-682-5507 
    help@eBrap.org


  • 31 May 2018 12:30 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical PH- and TBI-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).  The CDMRP provides PH/TBIRP execution management support for DHP core research program areas, including the Joint Program Committee 6/ Combat Casualty Care Research Program (JPC-6/CCCRP).  JPC-6/CCCRP provides strategic oversight for the PH/TBI funds associated with this funding Program Announcement.  The Defense Health Agency is working in collaboration with the U.S. Department of Veterans Affairs (VA) and other Federal agencies on research efforts to improve the lives of Service members and Veterans affected by traumatic brain injury, posttraumatic stress disorder, and other mental health conditions.

    The PH/TBIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  The FY18 PH/TBIRP Program Announcement and General Application Instructions for the following award mechanism is anticipated to be posted on the Grants.gov website in July 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the Government.

    http://cdmrp.army.mil/pubs/press/2018/18phtbipreann_limbic

    FY18 PHTBIRP Joint DoD and VA Long-term Impact of Military-relevant Brain Injury Consortium (LIMBIC)

    • Independent investigators at all academic levels (or equivalent)
    • Preproposal is required; application submission is by invitation only.
    • The objective of this funding opportunity is to support a single consortium to study a large cohort of TBI subjects to include Service members and Veterans.

    Required Focus Areas (each must be addressed in application)

    • Identification of differences in long-term neurological outcomes from blast-related vs. impact only TBI.
    • Identification of pathophysiological and biomarker signatures that may be predictive of long-term outcomes and healthcare utilization.
    • Analysis of existing biorepositories and/or biospecimens from a longitudinal cohort to identify novel biomarkers for chronic TBI.
    • Stratification and characterization of TBI subgroups based on recovery and neurodegeneration.
    • Analysis of existing DoD and VA TBI databases for correlations and associations of TBI comorbidities.

    Secondary Focus Areas (in no particular order)

    • Understanding the economic burden of TBI. 
    • Identification of potential differences between single vs. multiple TBI history on outcomes.
    • Identification of potential differences in long-term neurological outcomes from blast-related vs. impact-only TBI.
    • Identification of potential differences between individuals with exposure to repetitive low-level blast and those without.
    • Identification and investigation of neurodegeneration and TBI-associated comorbidities.
    • Evaluation of chronic mTBI biomarker profile(s) over time and injury severity.
    • Identification of potential variations in long-term outcomes in deployment-related vs nondeployment-related TBI.
    • Determination of whether a history of TBI is associated with lower performance metrics.
    • Maximum allowable costs (direct and indirect) are $25M via the DoD.
    • Up to an additional $5M per year for 5 years will be provided by the VA to VA sites, depending on availability of funds.
      • To be eligible for VA funding at a specific research site, a participating investigator must have a VA-paid appointment of at least five-eighths at the time of pre-application submission, unless a previous eligibility waiver has been granted.
    • Maximum period of performance is 5 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 30 May 2018 1:11 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $30 million (M) to the Department of Defense Spinal Cord Injury Research Program (SCIRP) to support innovative, high-impact spinal cord injury research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY18 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

     

    For FY18, SCIRP encourages applications that address the critical needs of SCI research and patient care in one or more of the following FY18 Focus Areas:

    *             Neuroprotection

    *             Biomarkers

    *             Bladder and bowel dysfunction and neuropathic pain

    *             Psychosocial issues relevant to SCI in individuals with SCI and their caregivers

    *             Rehabilitation and regeneration

    http://cdmrp.army.mil/funding/scirp

     

    Clinical Trial Award – Preproposal due July 9, 2018

    Independent investigators at all academic levels (or equivalent)

    *         Preproposal is required; application submission is by invitation only.

    *             Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.

    *             Preclinical data required for all clinical trial applications.

    *         Maximum funding of $3M for direct costs (plus indirect costs)

    *             Maximum period of performance is 4 years

    Investigator-Initiated Research Award – Preproposal due July 9, 2018

    Independent investigators at all academic levels (or equivalent)

    *         Preproposal is required; application submission is by invitation only.

    *         Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.

    *         Preliminary data required.

    *         Clinical trials not allowed.

    *         Maximum funding of $500,000 for direct costs (plus indirect costs)

    *         Maximum period of performance is 3 years.

    Qualitative Research Award – Preproposal due July 9, 2018

    Independent investigators at all academic levels (or equivalent)

    *         Preproposal is required; application submission is by invitation only.

    *         Fund qualitative research on military Service members and Veterans in the years following SCI.

    *         Qualitative research is defined as a form of social inquiry that focuses on understanding the way that people interpret and make sense of their experiences and the world in which they live (i.e., seek to understand the human experience).

    *         Preliminary data encouraged, but not required.

    *         Clinical trials not allowed.

    *         Maximum funding of $500,000 for direct costs (plus indirect costs)

    *         Maximum period of performance is 3 years

    Translational Research Award – Preproposal due July 9, 2018

    Independent investigators at all academic levels (or equivalent)

    *         Preproposal is required; application submission is by invitation only.

    *         Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.

    *         Preliminary data required

    *         The SCIRP TRA may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.

    *         Maximum funding of $1.25M for direct costs (plus indirect costs)

    *         Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website   (http://cdmrp.army.mil <http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507

    help@eBrap.org


  • 30 May 2018 1:11 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The OPORP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 OPORP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

    Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the Orthotics and Prosthetics Outcomes research community in one or more of the FY18 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY18 Focus Areas:

    • Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
    • Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
    • Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

    http://cdmrp.army.mil/pubs/press/2018/18oporppreann

    Clinical Research Award

    • Independent investigators at all academic levels (or equivalent)
    • Funding Level 1 may support pilot research that has the potential to make significant advancement towards clinical translation. Preliminary data are allowed but not required.
    • Funding Level 2 is supported by preliminary data and has the potential to make significant impact towards clinical translation.
    • Animal studies are not allowed.
    • Clinical trials are not allowed.
    • Funding Level 1:
      • Maximum funding of $350,000 for total costs.
      • Maximum period of performance is years.
    • Funding Level 2:
      • Maximum funding of $1.5M for total costs.
      • Maximum period of performance is years.

    Clinical Trial Award

    Independent investigators at all academic levels (or equivalent

    • Funding Level 1 may support pilot clinical trials for exploratory studies involving limited human exposure with the potential to make significant advancement towards clinical translation. Preliminary data are allowed but not required.
    • Funding Level 2 supports rapid implementation of clinical trials with the potential to make significant impacts on improving the health and well-being of Service members, Veterans, and other individuals with limb deficit.
    • Preclinical research is not allowed.
    • Funding Level 1:
      • Maximum funding of $350,000 for total costs.
      • Maximum period of performance is years.
    • Funding Level 2:
      • Maximum funding of $2.5M for total costs.
      • Maximum period of performance is years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 30 May 2018 1:10 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) to support critical traumatic brain injury (TBI)- and psychological health (PH)-related research and development efforts to benefit Service members, Veterans, and other beneficiaries of the military health system.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation appropriation.  The U.S. Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP) provides execution management support for DHA research program areas, including the Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP).  The managing agent for this Program Announcement is the CDMRP with strategic oversight from the JPC-8/CRMRP.

    The PH/TBIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18/19 PH/TBIRP Complex TBI Rehabilitation Research (CTRR) Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in June 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    The FY18/19 PH/TBIRP will solicit research applications for the following CTRR Focus Areas:

    • Mechanisms of Recovery following isolated or cumulative TBI(s) in Service member-relevant injuries:  Clinical research in human subjects that measures physiologic responses to cognitive rehabilitation with the intent to better understand how rehabilitation remediates cognitive or sensorimotor deficits, and ultimately to optimize rehabilitation prescription.

    Ecological Assessment:  Investigation of outcome measures focused on military-specific tasks that inform return-to-duty/participation decisions following rehabilitation in patients with TBI. 

    Cognitive Rehabilitation:  Evaluation of rehabilitation intervention effectiveness in remediating cognitive impairments and functional limitations after TBI. 

    http://cdmrp.army.mil/pubs/press/2018/18phtbipreann

    CTRR – Clinical Research Award (CTRR-CRA)

    Independent investigators at all academic levels (or equivalent)

    ·      Supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI.

    ·      Supported research can include preclinical studies using human subjects or samples and observational or mechanistic clinical research studies.

    ·      Clinical trials are not allowed.

    ·      Preclinical research using animals is not allowed.

    ·      Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

    Preproposal is required; application submission is by invitation only.

    ·      Maximum funding of $2.0M for total costs (direct plus indirect costs).

    • ·      Maximum period of performance is years.

    CTRR – Clinical Trial Award (CTRR-CTA)

    Independent investigators at all academic levels (or equivalent)

    ·      Supports small, single-site, Phase I clinical trials to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI in Service members, Veterans, and other individuals.

    ·      Interventions should be limited, existing, and manualized.  Studies may include seeking to optimize dosing in existing interventions.

    ·      Preclinical studies are not allowed.

    ·      Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

    Preproposal is required; application submission is by invitation only.

    ·      Maximum funding of $1.5M for total costs (direct plus indirect costs).

    • ·      Maximum period of performance is 2 years.

    CTRR – Clinical Trial Development Award (CTRR-CTDA)

    Independent investigators at all academic levels (or equivalent)

    ·      Supports design and development of the necessary research resources that will serve as a foundation for investigator-initiated clinical trials as described above under CTRR – Clinical Trial Award (CTRR-CTA)

    ·      Final supporting studies required for approval of Investigational New Drug Applications/Investigational Device Exemptions (IND/IDE-enabling) are allowed.  Other preclinical studies are not allowed. 

    ·      Clinical trials are not allowed within the period of performance of the CTRR-CTDA.

    ·      Must address one or more FY18/19 PH/TBIRP CTRR Focus Areas.

    Preproposal is required; application submission is by invitation only.

    ·     Maximum funding of $200,000 for total costs (direct plus indirect costs).

    • ·      Maximum period of performance is 1 year.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PH/TBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 22 May 2018 2:09 PM | Anonymous member (Administrator)

    FY18 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/funding/arp

    Clinical Trial Award – Preapplication due July 5, 2018

    • Investigators at or above the level of Associate Professor (or equivalent), or
    • Early-Career Investigator Partnering PI Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:
    • Must be in a current postdoctoral training position or have completed postdoctoral training by the  application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • Has the freedom to commit at least 50% time to the project
    • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
    • Applications in the following areas are strongly encouraged:
      • Behavioral cognitive, and other non-pharmacological therapies.
      • Pharmacological, genetic, and other biological treatments in ASD.
      • Dissemination/Implementation of clinically validated interventions.
      • Therapies to alleviate conditions co-occurring with ASD (i.e., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures).
      • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
      • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
      • Improve diagnosis across the lifespan.
      • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services.
    • Preliminary data relevant to the proposed clinical trial are required.
    • Pre-application is required; application submission is by invitation only.
    • Early-Career Investigator Partnering PI Option: Supports the development of young investigators pursuing or wishing to clinical trial.
    • The maximum allowable funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs)
    • The maximum period of performance is years
    • Early-Career Investigator Partnering PI Option:
    • Maximum funding of $1,155,000 in direct costs (plus indirect costs)
    • Maximum period of performance is years

    Clinical Translational Award – Preapplication is due July 5, 2018

    • Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
    • Applications in the following areas are strongly encouraged:
      • Behavioral cognitive, and other non-pharmacological therapies.
      • Pharmacological, genetic, and other biological treatments in ASD.
      • Dissemination/Implementation of clinically validated interventions.
      • Therapies to alleviate conditions co-occurring with ASD (i.e., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures).
      • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
      • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
      • Improve diagnosis across the lifespan.
      • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services.
    • Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs)
    • The maximum period of performance is 3 years

    Idea Development Award – Preapplication is due July 5, 2018

    • Investigators at or above the level of Assistant Professor (or equivalent) or
    • Multiple PI Option: 
      Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 
    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
    • Applications in the following areas are strongly encouraged:
    •  Preliminary Behavioral cognitive, and other non-pharmacological therapies.
    • Pharmacological, genetic, and other biological treatments in ASD.
    • Dissemination/Implementation of clinically validated interventions.
    • Therapies to alleviate conditions co-occurring with ASD (i.e., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures).
    • Interventions promoting success in key transitions to adulthood for individuals living with ASD.
    • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).
    • Improve diagnosis across the lifespan.
    • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services.
    • Preliminary data are required.
    • Pre-application is required; application submission is by invitation only.
    • Multiple Principal Investigator (PI) Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
    • The maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs)
    • For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed $500,000 in direct costs (plus indirect costs)
    • The maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 22 May 2018 2:08 PM | Anonymous member (Administrator)

    The FY18 Defense Appropriations Act provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

    The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.  Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

    ·        Develop treatments that improve outcomes for men with lethal prostate cancer

    ·        Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

    ·        Define the biology of lethal prostate cancer to reduce death

    ·        Improve the quality of life for survivors of prostate cancer

    http://cdmrp.army.mil/funding/pcrp

    Impact Award – Preproposal due July 19, 2018

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Preproposal is required; application submission is by invitation only.
    • Supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • The potential impact of the research is expected to be near-term, with the potential to transform the clinical management of prostate cancer within 5 years after the end of the award.
    • Proposed projects may include basic, translational, or clinical research, including small scale clinical trials.
    • Detailed transition plan to describe the pathway for moving the project’s findings to the next phase of development after the award is required.
    • Preliminary data to support feasibility are required.
    • Maximum funding of $750,000 for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Idea Development Award – Preproposal due July 6, 2018

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Or New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
    • Have the freedom to pursue individual aims without formal mentorship
    • Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award
    • Have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of terminal degree (excluding residency or family medical leave)
    • Preproposal is required; application submission is by invitation only.
    • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to eliminating death and enhancing the well-being of men with prostate cancer.
    • Emphasis is equally placed on Innovation and Impact.
    • Preliminary data are encouraged, but not required.
    • Clinical trials are not allowed.
    • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Maximum funding of $600K for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Physician Research Award – Letter of Intent due August 16, 2018

    • At the time of application submission, the PI must be either:
    • In the last year of an accredited graduate medical education program, either as a resident or fellow:
    • or
    • Within 3 years of having initiated an appointment as Instructor, Assistant Professor, or equivalent
    • Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
    • PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
    • PIs must have a designated mentor with an established research program in prostate cancer.
    • Institutions must provide at least 40% protection of PI’s time for research.
    • Projects that focus on basic research are highly encouraged.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • Maximum funding of $750,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.

    Early Investigator Research Award- Letter of Intent due August 16, 2018

    By March 31, 2019

    Postdoctoral Ph.D. or M.D. PIs:

    • Must have successfully defended a doctoral thesis or possess an M.D. degree
    • Have 3 years or less of postdoctoral research experience
    • Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
    • PIs must have a designated mentor who is an experienced prostate cancer researcher.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • Maximum funding of $200,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website.

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org



1717 K ST NW Suite 900

Washington, DC 20006

202-951-7701  |  admin@navref.org

Powered by Wild Apricot Membership Software